While cancer-focused pharma and biotech are busy presenting their latest research achievements at the ongoing American Society of Clinical Oncology (ASCO) meeting, Germany’s Merck KGaA (MRK: DE) ...

With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight.

Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, ...

Japanese drugmaker Eisai (TYO: 4523) today said it will strengthen and continue its venture investment business. Eisai ...

Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as ...

Market and contract research organization IQVIA has published its Global Oncology Trends report for 2024, projecting a ...

Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for ...

Dermatology and cosmetics company Pierre Fabre Laboratories has bought oncology specialist Vertical Bio, thus adding VERT-002 to its discovery pipeline.

Globally, the devastating and widespread impact of neurological disorders like Alzheimer's disease, epilepsy, Parkinson’s ...

The groups will work together to enhance Africa's vaccine infrastructure, with CEPI committing up to $145 million to ...

The US Food and Drug Administration yesterday approved Bristol Myers Squibb’s (NYSE: BMY) Breyanzi (lisocabtagene maraleucel ...

Chief Executive Officers of the world’s largest generic and biosimilar medicines companies recently met in Vienna, Austria, to provide strategic advice to the International Generic and Biosimilar ...